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1- INTRODUCTION 
Visfatin, also named nicotinamide phosphoribosyl transferase (NAMPT), is an adipokinehas been shown to possess 
anti-diabetic1, anti-tumor 2, and pro-inflammatory properties 3.Visfatin expression is increased in animal models of 
obesity and its plasma concentrations are increased in humans with abdominal obesity or type 2 diabetes mellitus 
4,5.Visfatin can regulate immune action and is involved in the NAD+ salvage pathway 6. 
It is well established that adipocytes have a more complex physiological role 7 and because blood vessels express 
receptors for most of the adipocyte-derived factors, adipose tissue seems to play a key role in cardiovascular physiology 
via the existence of a network of local and systemic signals 8.The relationship between cardiovascular diseases (CVD), 
obesity and metabolic syndrome was also supported by Gauvreau et al9 who mentioned that metabolic syndrome is 
characterized by changes in arterial blood pressure, glucose metabolism, lipid and lipoprotein profiles in addition to 
inflammation. They also reported that intra-abdominal (visceral) adipose tissue in particular, rather than peripheral, 
appears to be associated with global cardiometabolic risk. 
Visfatin may be related to the development of obesity-related diseases such as diabetes mellitus and cardiovascular 
disease 10. This suggestion was supported byDe Clercq et al11who reported that adipocytes produce large numbers of 
hormones, peptides, and other molecules that affect cardiovascular function, not only in an endocrine manner, but also 
by autocrine and paracrine mechanisms. In this review we summarized the main aspects of visfatin in cardiovascular 
diseases but first we discussed the relationship between visfatin and serum lipids because of the definite role of lipids in 
different cardiovascular diseases. 
2- VISFATIN AND SERUM LIPIDS: 
In our study12, we found that administration of visfatin, glibenclamide or metformin significantly (p < 0.05) decreased 
the levels of triglycerides(TG) and Very Low Density Lipoproteins (VLDL) in diabetic rats compared to diabetic 
control rats. Our finding was found to be in agree withFukuhara et al 1who found that visfatin stimulated the 
accumulation of triglycerides in pre-adipocytes similarly to cells treated with insulin.Our findings were also in 
agreement with Choi et al., 13who corroborates experimental data on the formation and release of visfatin by 
rosiglitazone.They found that the expression of visfatin mRNA in visceral fat deposits was elevated by rosiglitazone or 
fenofibrate treatments when compared to untreated fatty rats (P<0.05).Theysuggestedthat rosiglitazone and fenofibrate 
may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin and TNF-alpha.  Also our 
findings were supported by Sun et al14 who found that serum visfatin concentrations at baseline were positively 
correlated with serum triacylglycerols. Our results were also strongly supported by Hammarstedt et al15 who reported 
a 2-fold increase in plasma visfatin concentrations in individuals with type 2 diabetes mellitus (T2DM) compared with 
healthy controls.This was also found by other studies in patients with T2DM showed that visfatin plasma levels were 
significantly increased in T2DM compared with controls 16, 17, 18.However our results in controversy with Dogru et al19 
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and Pagano et al
20 who found no correlation between circulating visfatin on one hand and BMI, insulin, glucose and 
lipid levels on the other hand.However they found that visfatin levels increased significantly in the diabetics compared 
with controls and this finding support our finding in that visfatin reduced significantly serum levels of VLDL, 
cholesterol and triglycerides in diabetic rats and visfatin here may act as a counterregulator to serum lipids. 
Our results were in controversy with Pagano et al20in that circulating levels of visfatin were decreased by approx. 50% 
in obese patients compared with controls and a negative correlation was found between circulating visfatin levels and 
BMI in obese patients. This controversy can be explained by our suggestion that plasma visfatin is increased in 
diabetics in a trial to counteract elevated blood glucose as well as serum lipids but the plasma level of visfatin in normal 
subjects is so small that no effect of visfatin on serum biochemical parameters and this explanation is supported by 
Lopez-Bermejo et al, 
18 who found that visfatin levels were significantly increased in patients with long-standing Type 
1 diabetes mellitus (T1DM) compared with subjects with T2DM or non-diabetic subjects and in non-diabetic men. 
Also, we found that combination of visfatin with glibenclamide or metforminfurther reduced the levels of TG and 
VLDL in diabetic rats and significantly decreased total cholesterol in diabetic rats. Our findings were in agree with 
Fukuhara et al
1who found that circulating visfatin levels were shown to be strongly correlated with the amount of 
visceral adipose tissue (VAT) but they also found a weak correlation between plasma visfatin concentrations and the 
amount of abdominal subcutaneous fat.Our findings confirmed that visfatin decreases some serum lipids, so elevated 
visceral fat secretes more visfatin which in turn decreases serum lipids to prevent hyperlipidemia and this explanation 
was supported by Zahorska-Markiewicz et al21 who found that serum concentration of visfatin was significantly 
higher in obese women when compared to controls and they concluded that the observed increase of visfatin in obesity 
may be a counter regulation preventing further glucose increase. Our explanation was also supported by Jin et al22 who 
found that serum visfatin levels were significantly higher in obese subjects than in non-obese subjects.Our study was 
also supported by Berndt et al23 who showed that plasma visfatin concentrations correlated positively and significantly 
with body mass index and percentage body fat, as well as visfatin mRNA expression in VAT.These findings were 
supported by de Luis et al24who found thattotal cholesterol, low-density lipoprotein cholesterol, tumor necrosis factor-
α, and resistin levels are elevated in patients with visfatin levels above the median value. Our findings on serum lipids 
were also supported by De Luis et al25whofound a positive correlation between visfatin levels and LDL cholesterol 
(r=0.194; p<0.05) and C reactive protein (r=0.266; p<0.05) and a negative correlation with weight (r=-0.162; p<0.05). 
We concluded that visfatin has a significant lowering effect on some serum lipids in diabetic rats and we suggested that 
visfatin act as a counter regulator to elevated serum levels of glucose, cholesterol, VLDL and triglycerides.  
3- TRIAD OF VISFATIN, OBESITY AND CARDIOVASCULAR SYSTEM: 
Several epidemiological studies have clearly demonstrated that human obesity, a disease in which adipose tissue is 
largely represented, is a strong cardiovascular risk factor causally involved in the development of cardiovascular disease 
26, 27. 
Adipokine production and secretion were found by many studies to be increased in central obesity 28, 29, 30. This fact 
plays a pivotal role both in the pathogenesis of cardiovascular damage through adverse effects on hemostatic balance 
and vascular function 31, 32, 29, and in the amplification of inflammatory processes in vascular and nonvascular tissues 
29,33,28. It was also found that adipose tissue from individuals with central obesity synthesizes and releases increased 
amount of vasoactive substances such as angiotensinogen and endothelin-1 (ET-1) 34, 35.These findings were supported 
by Micić and Polovina, 36who reported thatobesity is a risk factor for various cardiovascular diseases including 
hypertension, atherosclerosis, myocardial infarction, heart failure and sudden heart death. They suggested that 
cardiomyopathy in obesity (adipositas cordis) appears due to accumulation of adipose tissue between the heart muscle 
fibers and degeneration of myocytes. They also reported that obesity is low inflammation state with increased adipokine 
production from truncal adipose tissue which causes endothelial dysfunction and insulin resistance. These findings and 
suggestions were also supported by many studies reported that obese subjects are characterized by insulin resistance, 
metabolic disorders, and vascular abnormalities which cooperate to induce high cardiovascular risk 37,38.  
In metabolic syndrome, there is a combination of central obesity, glucose intolerance, atherogenic dyslipidemia, and 
arterial hypertension 38, 39. These findings were also supported by Reaven et al31 andMatsuzawa29 who found that 
adipokines modulate angiogenesis via paracrine mechanisms and exert a role in the control of blood pressure, 
lipoprotein metabolism, coagulation, immunity and inflammation.  
In central obesity, abnormalities in fat mass are associated with a peculiar dysfunction of adipose tissue, responsible for 
endothelial dysfunction, pro-thrombotic tendency, low-grade chronic inflammation, and oxidative stress 40. These 
defects represent the main pathogenetic link between obesity and the increased risk of athero-thrombotic events 31, 32, 41. 
These findings were supported by Dahl et al42who reported thatboth oxidized low-density lipoprotein and tumor 
necrosis factor-α increased visfatin expression in THP-1 monocytes (THP1 is a human monocytic cell line derived from 
an acute monocytic leukemia patient) with a particularly enhancing effect when these stimuli were combined. They also 
found that visfatin increased matrix metalloproteinase-9 activity in THP-1 monocytes and tumor necrosis factor- α and 
interleukin-8 levels in peripheral blood mononuclear cells 
Micić and Polovina36reported that adipocytokines act synergistically or competitively with insulin, that explain their 
impact on insulin resistance. Inflammatory cytokines from adipose tissue could have influence on blood vessels 
endothelial function without their increase in plasma concentrations. These findings and suggestions were supported by 
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Nakamura et al
43who reported thatobesity leads to increased expression of pro-inflammatory adipokines and 
diminished expression of anti-inflammatory adipokines, resulting in the development of a chronic, low-grade 
inflammatory state and they suggested that this adipokine imbalance is thought to be a key event in promoting both 
systemic metabolic dysfunction and cardiovascular disease. 
As one of the inflammatory adipokines, visfatin in high circulating levels could be in healthy relations with 
cardiovascular risk factors, insulin resistance status and adiponectin in diabetic patients (44). These findings were 
supported byde Luis et al45 who found that visfatin was significantly correlated with total cholesterol and C reactive 
protein in female obese subjects. However they found that serum visfatin was not associated with the presence of 
metabolic syndrome (MS) or the accumulation of MS factors in female obese patients. However, Guzik et al4 reported 
that visfatin and other adipokines may act on immune cells leading to local and generalized inflammation and may also 
affect vascular (endothelial) function by modulating vascular nitric oxide and superoxide release and mediating obesity 
related vascular disorders (including hypertension, diabetes, atherosclerosis, and insulin resistance). They also reported 
that macrophages and T cells are populating adipose tissue which develops into almost an organized immune organ and 
these activated T cells further migrate to blood vessels, kidney, brain and other organs surrounded by infiltrated fat 
leading to their damage, thus providing a link between metabolic syndrome, inflammation and cardiovascular and other 
associated disorders.This link was also supported by Fukuhara et al 1 who reported that several studies showed 
involvement of visfatin in metabolic and vascular homeostasis.These studies werealso supported by Dahl et al42 who 
identified visfatin as a gene that was markedly enhanced in carotid plaques from symptomatic compared with plaques 
from asymptomatic individuals and they showed that visfatin was localized in areas that were rich in lipid-loaded 
macrophages. The relationship between visfatin and unstable lesions was also found in patients with coronary artery 
disease, demonstrating a strong visfatin immunostaining in lipid-rich regions within the material obtained at the site of 
plaque rupture in patients with acute myocardial infarction 42. They finally suggested that visfatin should be regarded as 
an inflammatory mediator, localized to foam cell macrophages within unstable atherosclerotic lesions, that potentially 
plays a role in plaque destabilization. 
Visfatin expression is also upregulated in plaque from the carotid artery of patients with symptoms of stroke and at the 
sites of plaque rupture in patients with acute myocardial infarction 42.The same study showed that balloon angioplasty, 
acutely injuring the plaques, caused visfatin levels to peak 4 hours after the procedure, receding back to basal levels 
after 24 hours. These results were supported by Curat et al 46who demonstrated that visfatin protein is released 
predominantly by macrophages in visceral adipose tissue. 
The relationship between visfatin, obesity and cardiovascular disease was also confirmed by Garten et al47 who 
reported that visfatin has been implicated in the pathogenesis of several acute or chronic inflammatory conditions such 
as atherosclerosis and CVD and it may act as a pro-inflammatory cytokine and potentially have a beneficial effect on 
insulin secretion. This study was supported by Spiroglou et al48 who found that visfatin expression was significantly 
higher in pericoronary adipose tissue samples compared with periaortic samples (p= 0.008).They also observed that 
visfatin was expressed in aortic and coronary artery tunica media(in vascular smooth muscle cells).They also detected 
visfatin in foam cells of atherosclerotic lesions noticeda positive correlation between visfatin expression and aortic 
atherosclerosis and a significant positive correlation between visfatin foam cell expression and atherosclerosis 48. They 
concluded that this correlation reflects the role of visfatin in inflammation and plaque destabilization. In a study by 
Malavazos et al
49 found that severely obese (OB) had thicker epicardial fat (EF) and higher visfatin and plasminogen 
activator inhibitor-1 (PAI-1) antigen concentrations than controls (P<0.0001) and EF thickness, log-visfatin and log-
PAI-1 antigen concentrations directly correlated with visceral adipose tissue (VAT) (P<0.0001). They also found that 
log-visfatin and log-PAI-1 antigen were correlated with EF thickness even after adjusting for indices of fat distribution 
(P<0.01 and P<0.001 respectively). They suggested that Epicardial fat thickness, an indicator of cardiac adiposity, may 
be significantly related to inflammatory adipo-cytokines in visceral-obese patients. All these studies confirmed the 
relationship between visfatin, lipids and cardiovascular diseases. 
4- VISFATIN AND HYPERTENSION: 
The relationship between visfatin and blood pressure emerged since few years. This relation was found by Filippatos et 
al
50 who found that plasma visfatin concentrations correlated with systolic blood pressure (rho = 0.28, p <0.001) and 
diastolic BP (rho= 0.27, p<0.001) in 186 Caucasian subjects (90 with Metabolic syndrome and 96 controls). This 
relation was supported by Seo et al51 who found that plasma visfatin concentrations were independently and positively 
associated with diastolic BP in 106 non-DM healthy Korean women, but not in 156 men.This relation was also 
supported by Ingelsson et al52 who observed a correlation between the prevalence of hypertension and visfatin(p = 
0.042).  
In a study on male albino rats we 53found that visfatin has insignificant inhibitory effect on blood pressure in normal 
rats. We found also that visfatin (1 nM) produced insignificant inhibitory effect on systolic and diastolic pressures in 
DOCA salt treated rats. Our results were in agreement with Wang et al54who found that no significant changes of 
circulating visfatin and no association between circulating visfatin levels and blood pressure in normotensive and 
spontaneously hypertensive rats. However they also found that visfatin expression in visceral fat tissue was slightly 
lower in stroke-prone spontaneously hypertensive rats (SHR-SP) compared with that in normotensive control Wistar-
Kyoto (WKY) rats 54. 
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We also found significant (P < 0.05) inhibitory effect of visfatin (10 nM) on both systolic and diastolic pressures in 
DOCA salt induced hypertensive rats. Our findings were in agree withEyileten et al55who found thatvisfatin levels 
were significantly correlated to systolic and diastolic blood pressures and ramipril treatment resulted in a significant 
decrease in plasma visfatin.  Our results werealso supported by the findings of Kralisch et al56who found a significant 
downregulation of visfatin expression during isoproterenol (nonselective beta agonist decrease the mean arterial blood 
pressure) treatment in 3T3-L1 adipocytes (cell line derived from mouse used in biological research on adipose tissue).  
However, our findings were in controversy with Wang et al54 in hypertensive rats, but we can explain this controversy 
by the different animal model, where they used spontaneously hypertensive rats instead of DOCA salt hypertensive rats 
in our study and we used different doses of visfatin. We also found that visfatin (100 nM) produced highly significant 
(P < 0.005) inhibitory effect on systolic and diastolic pressures in DOCA salt treated rats. Our results in agreement with 
Gunes et al
57 who found that the mean visfatin level was significantly higher in hypertensive patients and the serum 
visfatin levels in the pre hypertensive group were also significantly higher than in participants with normal blood 
pressure. They also found a significant positive correlation between visfatin and blood pressure.We can explain the 
elevated serum levels of visfatin in hypertensive patients by the suggestion that visfatin act to counteract the elevated 
blood pressure and as a compensatory mechanism done by visceral adipose tissue to decrease the high blood pressure to 
its normal value. Our suggestion is supported by the findings of Mazaheriounet al58who detected high levels of visfatin 
in patients with acute myocardial infarction. They concluded that pro-inflammatory cytokines such as visfatin may play 
a role in the development of atherosclerosis as well as destabilization of the atherosclerotic plaque.Our suggestion was 
also supported by explanation of Wang et al54who found that serum visfatin levels demonstrated a downward trend 
without statistical significance in stroke-prone spontaneously hypertensive rats (SHR-SP) in contradiction to a clinical 
study done by Lu et al59 showing an elevation of plasma visfatin levels in ischemic stroke patients. Wang et al54 
explained the contradiction by a big difference in examined time; in their study, serum visfatin was determined long 
before stroke occurrence, while in the clinical study, serum visfatin was determined after stroke, which perhaps reflects 
a compensatory reaction in the acute stage of illness.This means that visfatin level was elevated as a beneficial 
adipokine to counteract complicated hypertension which prove our findings. However, our results were in controversy 
withDogru et al19who found thatvisfatin plasma levels in newly onset hypertensive men andhealthy control men were 
not significantly different (p = 0.06). The latter study found that visfatin plasma levels did not correlate with the BP, 
BMI, lipid parameters, glucose, immunoreactive insulin, HOMA index or hsCRP levels either in patients or controls. 
We can explain this controversy by species differences where our study carried on rats but the latter study was a human 
study and also the latter study measured visfatin levels in normotensives and newly hypertensive men. In our study we 
examined the effect of visfatin on DOCA salt hypertensive rats.   
Also, our results were found to be in agreement with Filippatos et al50who found that plasma visfatin levels are 
increased in patients with metabolic syndrome compared with individuals that do not fulfill the criteria for this 
syndrome. However our results were in controversy with Kloting and Kloting 60who found that visfatin gene 
expression in visceral and subcutaneous adipose tissue is similar to that in lean control animals in the Wistar Ottawa rat, 
a model of polygenic metabolic syndrome with obesity, hypertension, dyslipidemia, hyperinsulinemia, and impaired 
glucose tolerance. However this controversy can be explained by the differences in used animals where we used normal 
male albino rats where they used a rat model with polygenic metabolic syndrome. 
Our results were also supported by Spiroglou et al48who found astatistically significant higher expression of visfatin in 
periaortic fat in cases of hypertension compared with normotension.Also, our results were in agreement with Rotkegel 
et al
61who found that hypertensive patients had significantly higher plasma visfatin level than the control group. 
However, they suggested that increased plasma visfatin concentration may play a significant role in the pathogenesis of 
hypertension in patients with visceral obesity. In controversy, we suggest that increased plasma visfatin level is a result 
not a cause and we assumed that visfatin secretion is increased to decrease the elevated blood pressure. Our last 
suggestion is supported by Yamawaki et al62who found that pretreatment with visfatin (100 ng/ml, 30 min) 
significantly inhibited noradrenaline-induced contraction in endothelium-intact rat aorta. They also found that visfatin 
(1-100 ng/ml) directly induced a relaxation in NA (100 nM)-pre-contracted aorta. They reported that the addition of 
visfatin to an organ bath resulted in a significant endothelium-dependent relaxation in both rat aortas and mesenteric 
arteries pre-contracted with NA. The vasorelaxant action of visfatin appeared to be independent of the insulin receptor, 
and was explained by the activation of endothelial nitric oxide synthase (eNOS) through phosphorylation at serine 1177 
via Akt and de-phosphorylation at threonine 475 62. These findings were also supported by Lovren et al 63who reported 
the stimulation of both eNOS activity and expression by visfatin, leading to enhanced production of nitric oxide and 
cyclic GMP formation in cultured human umbilical vein and coronary endothelial cells.Finally we concludedthat 
visfatin has a direct inhibitory effect on systolic and diastolic blood pressures in DOCA salt hypertensive rats in a dose 
dependent manner. We suggested that visfatin may have a protective role against hypertension and this role should be 
further evaluated by human studies. 
5- VISFATIN AND PREECLAMPSIA: 
Preeclampsia is a multi-system disorder of pregnancy, which is characterized by new onset hypertension (systolic and 
diastolic blood pressure of ≥ 140 and 90 mm Hg, respectively, on two occasions, at least 6 hours apart) and proteinuria 
(protein excretion of ≥ 300 mg in a 24 h urine collection, or a dipstick of ≥ 2+), that develop after 20 weeks of gestation 
in previously normotensive women 64, 65. Dependent on the systemic involvement, several other symptoms, such as 
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edema, disturbance of hemostasis, renal or liver failure, and the HELLP syndrome (hemolysis, elevated liver enzymes, 
and low platelet counts) also complicate the clinical picture 66. The relationship between visfatin and pre-eclampsia was 
studied by Fasshauer et al67who found that mean maternal visfatin serum levels adjusted for maternal age were about 
2-fold upregulated in preeclampsia (31.1 ± 23.4 μg/L) compared with controls (15.7 ± 23.1 μg/L). In contrast, in other 
study Hu et al68 found that plasma visfatin levels were significantly lower in preeclampsia compared with non-pregnant 
controls (p = 0.004) and pregnant controls (p < 0.001). They also found that women with severe preeclampsia had a 
significantly lower serum visfatin level than those with mild preeclampsia (p = 0.037). These contradictory results may 
be attributed to different subject characteristics or to the time of pregnancy when preeclampsia occurred. For example, 
in the first study gestational age at the time of blood sampling was approximately 30 weeks vs 35 weeks in the second 
study, whereas the BMI was 22.5 kg/m2 in the first study vs 27.8 kg/m2 in the second study. Therefore, these studies 
are not directly comparable. Furthermore, there is evidence that the placenta expresses visfatin 69,70. Consequently, there 
may be a decrease in visfatin transfer as placental function worsens 71. This hypothesis may explain the observation that 
women with severe preeclampsia had a significantly lower serum visfatin level than those with mild preeclampsia 68. In 
a recent study by Ferreira et al72, serum visfatin levels at 11–13 weeks were found increased in women who develop 
PE by a mechanism unrelated to impaired placental perfusion.However further studies are needed to elucidate the exact 
relationship between serum visfatin and pre-eclampsia and the exact role of visfatin in development of eclampsia. 
6- VISFATIN AND CARDIOPROTECTION: 
Increased circulating adipocytokines secreted from visceral fat may have cardioprotective effects.Now, visfatin is well 
known in the association between obesity and cardiovascular risk and was demonstrated to improve cardiovascular risk 
factors 73.It was demonstrated that visfatin exhibited direct cardioprotective effects in a murine  in vivo 
(ischemia reperfusion) I/R model, infarct size being reduced by 50% following treatment with a single 
intravenous bolus dose of visfatin (74).These findings were supported by Yuet al75whodemonstrated that circulating 
visfatin levels at admission in patients with acute myocardial infarction are associated with thrombotic occlusion of 
infarct related artery.The latter study was also supported by the findings of Pala et al76who found that circulating 
visfatin levels were significantly lower in cases of both CVD (Cerebrovascular Disease) and IHD (Ischemic Heart 
Disease) with respect to controls (p= 0.014 and p= 0.035 respectively). They suggested that visfatin has a major effect 
on the development of cardiovascular disease and they concluded that the measurement of visfatin with other 
adipokines could be considered for predicting the risk of developing major cardiovascular events. 
Another study done by Chang et al77found that visfatin was expressed in cardiomyocytes as well as cardiac fibroblasts. 
These findings were supported by Filippatos et al78who found thatthe atherogenic small dense low density lipoprotein 
subclasses (sdLDL-C) were significantly increased in the top visfatin tertile compared with the lower 
tertiles.Thesefindings were also supported by Xiao et al79who demonstrated that visfatin counteracted H2O2 -induced 
apoptotic damage in cardiomyocytes in a time-dependent manner. They demonstrated that visfatin pretreatment 
attenuated H2O2 -induced DNA fragmentation, phosphatidyl serine exposure, and mitochondrial membrane potential 
depolarization. Xiao et al79mentioned thatbiochemical studies on cardiomyocytes showed improved cell viability and 
reduced caspase-3 activation caused by visfatin pretreatment and visfatin specifically suppressed the mitochondria-
dependent apoptotic pathways, as characterized by changed levels of p53 and up-regulated the protein levels of 
phosphorylated AMPK. These findingsproved that visfatin plays a critical role in cardioprotection by suppressing 
myocardial apoptosis via AMPK activation.These studiessupport our suggestion that visfatin act as a beneficial 
adipokine protect the heart from myocardial injury and its plasma level can lead to a serious change in cardiovascular 
system. This suggestion was supported by Xiao et al79 who reported that increased circulating adipocytokines 
especially visfatin may confer cardioprotective effects, that is, the so called ―obesity paradox‖. 
7- MECHANISM OF ACTION OF VISFATIN: 
The actions of visfatin have been linked to activation of Akt (protein kinase B)andp44/42 (mitogen-activated 
protein kinase)signaling pathways that have been linked to cardioprotection 80,81,82. It was reported that 
visfatin-induced glucose uptake into kidney mesangial cells via insulin receptor activation and subsequent 
Akt phosphorylation83. In human EC visfatin was shown to induce cellular proliferation through increased 
VEGF and MMP-2/9 production via PI3K-Akt and p44/42 signaling 84. 
It was also reported that visfatin gene is transcribed in response to hypoxia, an effect that is mediated by hypoxia-
inducible factor (HIF) 85,86, raising the possibility that visfatin may be upregulated in response to myocardial ischaemia. 
The upregulation of HIF has recently been established as a major mediator of cardioprotection 87.This means that 
hypoxia-inducible factor (HIF)-1α, which regulates the transcription of hypoxia-activated genes, may play a 
pivotal role in cardioprotection  88. It was reported that hypoxia markedly enhancedvisfatin expression in both 
3T3-L1 adipocytes 85 and MCF7 breast cancer cells 86, and that this involved activation of the HIF-1α 
pathway. These raise thepossibility that visfatin expression may be upregulated as aresult of myocardial 
ischaemia (and induction by HIF-1α), a scenario that has been invoked previously for leptin 89, apelin90 and 
adiponectin91,92. 
Visfatin was also reported to block neutrophil apoptosis in experimental inflammation and clinical 
sepsis93.Apoptosis is a key feature of myocardial ischemia reperfusion (I/R) induced injury80. Similarly, 
visfatin was also shown to reduce apoptosis in vascular smooth muscle cells 94 and in human umbilical vein 
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endothelial cells (HUVECS)95, in the case of the latter via Akt and Erk1/2 mediated mechanisms. Thus visfatin 
acts as a growth promoter, enhances Akt and p44/42 signaling, and blocks apoptosis, and may, like leptin 
and adiponectin, be produced by the heart itself.  
Visfatin-induced myocardial protection was also found tobe dependent upon PI3K and MEK 1/2 activation74. 
Furthermore, in murine ventricular cardiomyocytes subjected to hypoxia-reoxygenation, Lim et al74 
demonstrated that visfatin  administered at reoxygenation reduced cell death substantially and this effect was 
mediated by the inhibition of the mitochondrial permeability transition pore (MPTP) opening, a non-specific 
mitochondrial channel, its opening in the first few minutes of myocardial reperfusion being a critical determinant of 
cardiomyocyte death.These effects could be blocked by the phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin, 
and theMEK1/2 inhibitor, U0126. These observations were confirmed by Hsu et al 96 who showed that the expression 
of visfatin in the heart is decreased by ischemia/reperfusion and pressure overload.Theyproposed that visfatin may 
protect against myocardial infarction by regulating autophagy in the cardiomyocytes. These findings were also 
supported by Smith and Yellon 97who reported that visfatin exerts a powerful direct cardioprotective effect via 
cellular mechanisms that involve the activation of RISK (Reperfusion Injury Salvage Kinase) pathway 
components which terminate on the MPTP (mitochondrial permeability transition pore). 
Visfatin/Nampt, may also be expected to upregulate NADbiosynthesis thereby enhancing energy metabolism and redox 
biochemistry, factors that underpin the tolerance of myocardial tissue to ischaemicinjury. This expectation was 
supported by Rongvaux et al98whoreported that mice lacking expression of Nampt was found to be more susceptible to 
genotoxicand oxidative stress, and it has been proposed thatNampt may be required for cell survival in 
stressfulsituations such as inflammation.These findings were also supported by Nadtochiy et al99who found 
thatcardiac-specific overexpression of visfatin in mice had increased the NAD+ content in the heart, prevented 
downregulation of visfatin and reduced myocardial infarction size and apoptosis upon ischemia and 
ischemia/reperfusion. They also reported that inhibition of visfatin blocked ischemic preconditioning- induced 
cardioprotection. 
8- VISFATIN AND CORONARY ARTERY DISEASE (CAD): 
Visfatin has been shown to be produced by immune cells such as neutrophils and macrophages usually involved in the 
pathophysiology of acute coronary events 100,101.The pathophysiological basis for the association between NAMPT 
levels and CAD is still unclear, as both cardioprotection 85,102 and deleterious effects of NAMPT on the cardiovascular 
system have been reported 42,103. Also, Visfatin has been suggested to enhance insulin sensitivity, but its potential role in 
plaque destabilization may counteract this 9. 
Chenget al
104 found that tissue level of visfatin was significantly higher in coronary heart disease (CHD) patients 
relative to control subjects and significantly higher tissue levels of visfatin found in abdominal fat depots compared 
with those from epicardial fat in CHD patients. These findings were supported by Liu et al105 who demonstrated that 
patients with coronary artery disease have increased plasma levels of visfatin and that these levels were significantly 
elevated in patients with acute coronary syndromes. However, the latter study in controversy with Choi et al106who 
found that visfatin levels were not significantly different between patients with CHD and control subjects and visfatin 
levels were not associated with any variables of the metabolic syndrome. Also, Rho et al107found that visfatin 
concentrations were associated with insulin resistance but not with coronary calcification. However another study by 
Zhong et al
108 found a positive association between visfatin and metabolic syndrome (MS), mainly among individuals 
with carotid atherosclerosis. They also found that visfatin was an independent risk factor for augmented carotid intimal-
media thickness. The last study was supported by Fu et al109 who found that plasma visfatin level may be related to the 
pathogenesis of CAD and detection of plasma visfatin might be helpful for early diagnosis of CAD, and patients with 
higher plasma visfatin level may have more severe coronary lesion. These studies were also supported by Spiroglou et 
al
48who found thatdecreased coronary VSMC (Vascular Smooth Muscle Cell) visfatin expression was associated with 
acute coronary occlusion (p= 0.016). The latter study demonstrates that visfatin may act as a beneficial adipokine 
preventing the occurrence of coronary artery occlusion. However this explanation is not supported by Maury and 
Brichard 
110 who suggested that visfatin may work as a pro-inflammatory cytokine being implicated into the 
pathogenesis of several acute or chronic inflammatory conditions, such as atherosclerosis and CVD. In a recent study, 
Saddi-Rosaet al
111 confirmed that circulating NAMPT levels are associated with CAD in type 2 diabetic patients. Also, 
Filippatos et al 
78 observed a positive association between visfatin tertiles with waist circumference and blood pressure, 
as well as with total cholesterol and triglyceride levels, but not with apolipoprotein C-III. Their results support a role for 
visfatin in the detection of subjects with many metabolic abnormalities, which result in increased CVD risk. 
9- ANGIOGENIC EFFECTS OF CHRONIC VISFATIN THERAPY: 
The relationship between adipokine and angiogenesis was reported by Reaven et al31 andMatsuzawa29who found that 
adipokines modulate angiogenesis via paracrine mechanisms. The role of visfatin in angiogenesis was supported by 
Kimet al
103 who reported that chronic visfatin therapy has been found to promote angiogenesis in endothelial cells both 
in vivo and in vitro and this has been suggested to be a potential mechanism for the neovascularisation of 
atherosclerotic plaques or adipose tissue in the presence of obesity. Subsequent experimental studies suggest that the 
mechanism underlying this angiogenic effect may relate to increased gene expression and elevated protein levels of 
vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2/9 (MMP) 84. Interestingly, the angiogenic 
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effect induced by visfatin and the associated upregulation of VEGF and MMP2/9 appears to be dependent on the 
activation of Akt and Erk1/2 95, 102, protein kinases that have been linked to cardioprotection when activated acutely 112. 
10- ROLE OF VISFATIN IN REGULATION OF VASCULAR TONE: 
Adipokines secreted by visceral, subcutaneous, and perivascular adipocytes are involved in the regulation of vascular 
tone by acting as circulatory hormones (leptin, adiponectin, omentin, visfatin, angiotensin II, resistin, tumor necrosis 
factor-α, interleukin-6, apelin) and/or via local paracrine factors (perivascular adipocyte-derived relaxing and 
contractile factors) 113.In fact, visfatin/PBEF/Nampt is released by a wide series of cell types, including activated 
monocytes/macrophages that can directly interact with vascular cells 113. 
The conversion of VSMCs (Vascular Smooth Muscle Cell)from a proliferative, noncontractile state to a 
nonproliferative, contractile state is essential for conferring vasomotor function to developing arteries94and promotes 
VSMC proliferation in perivascular adipose tissue by a paracrine mechanism 115. Thus, proliferation and differentiation 
processes in VSMCs under physiological or pathological conditions are important for the understanding of remodeling 
in diseased arteries. Both exogenous and endogenous visfatin seem to potently regulate the biological functions of 
VSMCs116.These findings were supported by Vanet al94who reported that vascular smoothmuscle maturation from a 
proliferative non-contractile phenotype to a non-proliferative contractile one has been found to be dependent on the 
presence of visfatin/ PBEF. 
Vascular effects are both chronic and acute: chronic exposure to high visfatin concentrations—such as in obesity and in 
type 2 diabetes mellitus—promotes endothelial dysfunction, angiogenesis and atherosclerotic plaque instabilization40, 
whereas acute visfatin administration stimulates eNOS expression and activity in endothelial cells 62and directly 
protects cardiomyocytes against the detrimental effects of acute ischemia-reperfusion injury117. 
Endothelial function improved during the first month after transplantation, and the degree of improvement correlated to 
reductions in circulating visfatin 118.In a study by Wang et al115visfatin was found to have a significant relaxingeffect 
on isolated arteries and stimulates growth of vascular smooth muscle cells.These findings were supported by 
Yamawaki et al
62 who found that visfatin induced relaxation in mesenteric arteries of rats, suggesting that visfatin is 
effective in resistance vessels.These findings indicate that, besides circulating visfatin/PBEF/Nampt, locally 
synthesized visfatin/PBEF/Nampt may also exert a relevant paracrine action in regulating the vascular function 119. 
These findings were also supported by Maenhaut and Van de Voorde 120 who found that visfatin can also directly 
affect vascular contractility and induced endothelium-dependent vasorelaxation in rat isolated aorta through NO 
production.  
11- VISFATIN AND ATHEROSCLEROSIS: 
Atherosclerosis is a chronic inflammatory response in the arterial wall, in large part due to the accumulation of 
macrophages and promoted by low-density lipoproteins 121.Controversial results exist about the expression, circulating 
levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in 
diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels 
of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of 
visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, 
inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, 
discrepancies and lack of correlation between commercially available visfatin assays have been reported 71. 
Salcedoet al 
122
 and Chen and Greene 
123reported that visfatin dose-dependently stimulate MCP-1 production via NF-
kappaB and PI3Kinase pathways, but not via MEK pathways. Their observations add to visfatin’s pro-angiogenic and 
pro-atherogenic role in human endothelium.Clinical reports have highlighted the relationship existing between visfatin, 
atherosclerosisand atherogenic plaque instability
42
.They found that both oxidized LDL and TNF-alpha increased 
visfatin expression in THP-1 monocytes, with a particularly enhancing effect when these stimuli were combined. 
Visfatin also increased MMP-9 activity in THP-1 monocytes andTNF-alpha and IL-8 levels in peripheral blood 
mononuclear cells. MMP and inflammatory cytokines play an important role in atherogenesis and plaque 
destabilization. The marked induction of these mediators by visfatin in cells with relevance to atherosclerotic lesions 
suggests that visfatin, showing enhanced expression in symptomatic plaques, could be an important mediator in these 
processes42. They suggested that visfatin should be regarded as an inflammatory mediator, localized to foam cell 
macrophages within unstable atherosclerotic lesions, that potentially plays a role in plaque destabilization. 
This relationship was supported by Kim et al124 who found that visfatin accelerates monocyte adhesion to endothelial 
cells by upregulating intercellular (ICAM-1) and vascular (VCAM-1) cell adhesion molecule-1 due to ROS 
overproduction, suggesting a possible role for visfatin in the development of atherosclerosis.They also reported that 
visfatin-mediated induction of these molecules was mainly regulated by nuclear factor- kappaB (NF-kappaB). Xia et 
al
125 reported a corresponding mechanism for visfatin-induced endothelial dysfunction in coronary artery endothelial 
cells, through lysosome-dependent lipid-raft signaling, and subsequent activation of NADPH oxidase and ROS 
production.These results were also supported by a study involved 139 Chinese patients with metabolic syndrome (40 
with carotid plaques and 99 without carotid plaques), serum visfatin levels were found greater in those with carotid 
plaques (p < 0.001)108. They also found that visfatin independently correlated with maximum carotid intima media 
thickness. In another study involved 29 T2DM patients without macroangiopathy, 33 T2DM patients with 
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macroangiopathy, and 22 non-DM controls,Alghasham and Barakat 126 found that serum visfatin was significantly 
higher in non-complicated T2DM subjects compared with controls and macroangiopathic T2DM patients. They 
reported that the difference in visfatin levels between macroangiopathic T2DM patients and controls was non-
significant. These findings were supported by Kadoglou et al127who found that high visfatin and low ghrelin serum 
levels were significantly associated with advanced carotid atherosclerosis in patients with T2DM. They also reported 
that these adipocytokines were independently associated with carotid intima-media thickness (CIMT), implicating their 
role as novel atherosclerotic biomarkers and providing another important link between adiposity and 
atherosclerosis.These results were also supported by Romachoet al128who found that visfatincan promote vascular 
smooth muscle inflammation, being associated with a potential role in vascular dysfunction and inflammation 
associated with some metabolic disorders. So they suggested that visfatin may have a direct role in vascular dysfunction 
and inflammation through iNOS upregulation. 
The mechanism of action of visfatin in atherosclerosis was mentioned by Adya et al95 who found that visfatin 
significantly increased NF kappaB transcriptional activity (p < 0.001) and endothelial cells pre-incubated with visfatin 
(dose dependently) for 16 h and then subjected to TNF-alpha (10 ng/mL) for 2 h revealed significant inhibition of TNF-
alpha-induced NF-kappaB transcriptional activity by visfatin. They also found that in human umbilical vein endothelial 
cells, visfatin significantly and dose-dependently up-regulated gene expression and protein production of vascular 
endothelial growth factor (VEGF) and (Matrix metalloproteinases) MMP-2/9 and down-regulated expression of tissue 
inhibitors of MMPs (TIMP-1 and TIMP-2) 84. Furthermore, inhibition of NFkappaB inhibitor significantly negated 
visfatin-induced matrix metalloproteinases (MMP)-2/9 mRNA expression, protein levels and activity (p < 0.001) 
95.These findings were supported by Dahl et al 42who suggested that visfatin might trigger plaque rupture by 
accumulating in atherosclerotic plaques where it stimulates monocyte metalloproteinase activity.  
Cirillo et al
129also demonstrated that visfatin induced transcription of mRNA for TF (Tissue Factor) by Real Time PCR 
and this adipokine promoted surface expression of TF that is functionally active since they measured increased 
procoagulant activity. These results indicated that visfatin induced a procoagulant phenotype in human coronary 
endothelial cells by promoting TF expression. Their observations support the hypothesis that this adipokine might play 
a relevant role as an active partaker in athero-thrombotic disease. These suggestions were supported by studies in 
different populations suggesting that high levels of circulating NAMPT are positively associated with atherosclerosis-
related metabolic phenotypes, as well as with the 10-year CVD Framingham risk score 130,131,78. These results was also 
supported by a recent study by Saddi-Rosa et al111who reported thatvisfatin has emerged in the last few years as a 
novel adipokine potentially implicated in the pathogenesis of atherosclerosis. 
12- VISFATIN AND RENIN ANGIOTENSIN SYSTEM: 
A study made by Storka et al132found that the release of visfatin from isolated human adipocytes, skeletal muscle cells 
and human umbilical vein endothelial cells (HUVEC) was 1.6-fold increased after incubation with lisinopril (ACE 
inhibitor) and about 2.0-fold increased with telmisartan (Angiotensin II receptor antagonist) and valsartan (Angiotensin 
II receptor antagonist with more selectivity on AT1). However in the same study, differences regarding in vitro PPARγ 
(peroxisome proliferator-activated receptor gamma) binding affinity did not affect the release of visfatin into 
supernatant media from adipocytes or skeletal muscle cells, which was detectable for all ARB (angiotensin receptor 
blockers) and ACE-I (Angiotensin converting enzyme inhibitors) under study. Thus, the functional metabolic net effect 
in patients may also differ to some degree from the in vitro results obtained. These findings were previously supported 
by Takebayashi et al133found that visfatin was also negatively correlated with circulating aldosterone. This finding was 
supported by Yilmaz et al 134who reported an association betweenelevated plasma visfatin and endothelial dysfunction 
attributed to chronic renal disease.These findings suggest that visfatin has a specific role in renin angiotensin system. 
Our suggestion is supported by the findings ofNüsken et al 135 who found that loss of renal function is accompanied by 
increased circulating active visfatin concentrations. These results were confirmed by Huang et al
136
who found 
thatvisfatin treatments increasedrenin, angiotensinogen (AGT), AT1 mRNA, and AGT, AT1 protein expression, as well 
as Ang II levels in a dose-dependent manner but did not affect ACE and AT2 mRNA levels in cultured rat mesangial 
cells. Our suggestion is also supported by a study done by Chang et al77 who found that Ang II treatment induced the 
increased expression of visfatin and brain natriuretic peptide in a dose- and time-dependent manner in cardiomyocytes 
and pretreatment with AT1-R antagonist telmisartan completely blocked Ang II-induced visfatin expression 
increasement. The increased visfatin expression was also blocked by the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathway inhibitor AG490 77. They concluded that visfatin expression was increased mainly 
through the AT1-R-JAK/STAT pathway in the process of Ang II-induced cardiomyocyte hypertrophy. Thus the role of 
visfatin in renin angiotensin system become well established but due to lack of studies on this aspect, the exact 
mechanism of action on the elements of this system need further studies.  
13- VISFATIN AND HEART FAILURE (HF): 
Ina study population consisted of 28 males with systolic HF referred for cardiopulmonary exercise testing and 23 
controls, Straburzyńska-Migaj et al137 found that concentrations of visfatin and high-density lipoprotein cholesterol 
(HDL-cholesterol) in the HF subjects were significantly lower (p≤0.01) than in controls.They also found significant 
differences in mean levels of visfatin between controls and heart failure patients. These results were supported 
byanother study involvingeighty-seven nondiabetic patients under PD (peritoneal dialysis) in which Karakan et 
al
138found that left ventricular mass index (LVMI) was correlated with body mass index, systolic blood pressureand 
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serum visfatin levels (r = 0.49, p = 0.03).Theyconcluded that Serum visfatin might be a sensitive marker than HOMA-
IR(homeostatic model assessment-insulin resistance)evaluations for cardiac performance in nondiabetic PD patients. 
14- VISFATIN AS A CARDIOVASCULAR PROTECTOR: 
Drugs as angiotensin converting enzyme inhibitors (ACEI), thiazolidinediones (glitazones) or angiotensin-II receptor 
antagonists, generally associated with the adequate hypolipidemic (statins, fibrates) or antiobesity (orlistat, sibutramine, 
rimonabant) medication, would increase those adipocytokines with anti-inflammatory and insulin-sensitizing properties 
(i.e. adiponectin or visfatin), while reducing pro-inflammatory and thrombogenic cytokines (as leptin, tumor necrosis 
factor [TNF]-alpha, plasminogen activator inhibitor 1 [PAI-1]). Thus, these pharmacologic therapeutic approaches 
would have a beneficial effect in order to diminish morbidity-mortality and improve the prognosis of patients with said 
diseases, all of them related to high cardiovascular risk 139. These findings were supported by Nakou et al140who 
reported that verapamil SR/trandolapril combination together with sibutramine resulted in significant reductions in 
visfatin plasma levels at the end of a 6-month treatment. They also found that the reduction was correlated with the 
decrease in body mass index. 
Recent evidence suggests that visfatin may be responsible for a number of different cardiovascular effects, depending 
on the cell type and the duration of therapy, one of which includes the ability to protect the myocardium from the 
detrimental effects of acute ischaemia-reperfusion injury117. As such visfatin may not only provide a potential new 
target for acute cardioprotection but it may also act as an anti-diabetic agent with a unique mechanism of action, thereby 
offering a potentially novel drug target for the diabetic patient that experiences an episode of acute myocardial 
ischaemia-reperfusion injury. These findings were also supported by Lovren et al63whoreported thatinjection of a 
plasmid containing visfatin in a mouse model of unilateral limb ischemia results in improved limb perfusion as 
compared to untreated animals.However a recent study by Cantarini et al141found thatleptin, adiponectin and visfatin 
are increased in idiopathic recurrent acute pericarditis (IRAP) patients versus healthy controls and they suggested that 
these adipokines might be involved in IRAP pathogenesis and that a possible increased cardiovascular risk in these 
patients, through an early onset atherosclerosis, should be kept in mind. 
CONCLUSION: 
In this review we concluded that visfatin has a lipid lowering effect as well as a glucose lowering effect. This effect was 
found to beneficial in diabetic persons who are liable to cardiovascular disease. Visfatin was also proved a protective 
effect in atherosclerosis which can be utilized as a drug in clinical medicine. A beneficial effect of visfatin was also 
found as a cardioprotective in case of myocardial infarction which is a serious problem. The valuable effect of visfatin 
as antihypertensive indicates further studies in human. The role of visfatin renin angiotensin system can explain the 
beneficial effect of visfatin in regulation of blood pressure. We suggest further studies of visfatin therapy in human for 
control of hypertension. 
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